BPA Call 36E79719A0032-36C24220N0479
Award Date
4/8/20
Potential Completion Date
4/13/20
Potential Value
$66K
Federal Agency
Veterans Integrated Service Network 2
Awardee
Horizon Therapeutics Usa, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Syracuse, NY 13210, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Horizon Therapeutics USA Inc. for the drug KRYSTEXXA 8MG/ML VIAL. The order is placed against Horizon's pre-existing General Services Administration (GSA) Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The order has a firm fixed price of $74,537.76 and a completion date of May 31, 2024. Horizon Therapeutics USA Inc. is a global biotechnology...
The U.S. Department of Veterans Affairs (VA) awarded a $76,896.72 firm fixed-price delivery order to Horizon Therapeutics USA, Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The award is part of Horizon's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) and is placed by the VA's Veterans Integrated Service Network (VISN) 5. This delivery order supports the VA's mission to provide comprehensive healthcare services to the veteran population, as KRYSTEXXA is...
This is a firm fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Horizon Therapeutics USA Inc., a global biotechnology company, under the company's existing Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The $37,268.88 award is for the delivery of KRYSTEXXA 8MG, a specialty medication used to treat chronic gout, to support healthcare services for veterans. This delivery order is placed against Horizon's $31.375 million...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed-price delivery order to Horizon Therapeutics USA, Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The $55,903.32 order is placed against Horizon's existing General Services Administration (GSA) Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). This delivery order will provide the VA with pegloticase injections to treat chronic gout in eligible veterans through...
This contract award is for the delivery of KRYSTEXXA 8MG, a specialty pharmaceutical product, to the United States Department of Veterans Affairs (VA). The contract, valued at $37,268.88, is a firm fixed-price delivery order placed by the VA's Veterans Integrated Service Network 5 (VISN 5) against the prime contractor Horizon Therapeutics USA, Inc.'s Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). Horizon Therapeutics USA, Inc. is a global biotechnology...
This delivery order for $55,903.32 was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 to Horizon Therapeutics USA Inc. against the company's Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The firm fixed price order, with no set-aside designation, is for the medication KRYSTEXXA 8MG and aims to supply VHA hospitals and clinics in La Vergne, Tennessee with this orphan disease treatment through...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded a firm fixed price delivery order valued at seventy-one thousand eight hundred eighty-five dollars and sixteen cents ($71,885.16) to Horizon Therapeutics USA Inc. under the company's Pharmaceuticals and Drugs Federal Supply Schedule contract. The order is to provide KRYSTEXXA 8MG for the treatment period of December 27, 2023 through December 29, 2023 and will be performed in La Vergne,...
The Department of Veterans Affairs Veterans Health Administration awarded a $131,372.30 firm fixed price delivery order to Horizon Therapeutics USA Inc., a foreign-owned for-profit organization, for the provision of KRYSTEXXA medication. This order was placed against Horizon Therapeutics' Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has no set-aside designation. Horizon Therapeutics has a $18 million Blanket Purchase Agreement against the...
This is a firm fixed-price delivery order awarded to Horizon Therapeutics USA, Inc. by the U.S. Department of Veterans Affairs (VA) under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract is for the supply of KRYSTEXXA (pegloticase), a medication used to treat chronic gout. The delivery order has a ceiling value of $76,896.72 and a completion date of March 4, 2025. Horizon Therapeutics USA, Inc. is the prime contractor for this award, and there are no specific...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded Horizon Therapeutics USA Inc. a $71,885 delivery order against the company's Pharmaceuticals and Drugs Federal Supply Schedule contract. The delivery order is for KRYSTEXXA 8MG to be provided between September 29 and October 3, 2023 at Horizon's facility in La Vergne, Tennessee. The contract utilizes firm fixed pricing and does not appear to include any set-aside designations. ...